InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,244.80
(
0.27%
)
Dow Jones
39,872.99
(
0.17%
)
Brent Oil
82.22
(
-0.28%
)
Bitcoin
69,891.93
(
-0.34%
)
Post# of 251888
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: drbio45 post# 119344

Wednesday, 05/04/2011 1:39:49 PM

Wednesday, May 04, 2011 1:39:49 PM

Post# of 251888
The real issue for YM is that once the Incyte drug is approved, then going up against a placebo in their Ph III is likely off the table.

If they have to go head-to-head then they are faced with the murkiness of a non-inferiority trial and in addition they will probably have to pay the (doubtless obscene) price that INCY will be charging for ruxolitinib for the patients in the comparator arm.

Peter

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up